within Pharmacolibrary.Drugs.ATC.M;

model M01AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Clofezone is a combination drug consisting of clofexamide (a nonsteroidal anti-inflammatory drug, NSAID) and phenylbutazone, previously used as an analgesic and anti-inflammatory agent for the treatment of musculoskeletal pain and arthritis, primarily in Europe. It is no longer widely marketed or approved due to concerns about safety, especially related to phenylbutazone.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for clofezone have not been reported in published literature. The following values are rough estimates based on pharmacokinetic properties of structurally/functionally related NSAIDs (e.g., phenylbutazone, clofexamide). Parameters represent adults, typical oral administration.</p><h4>References</h4><ol><li><p>Reinicke, C, et al., &amp; Wessel, G (1984). [Comparative studies on the bioavailability of various drug forms of phenylbutazone and clofezone (Perclusone)]. <i>Die Pharmazie</i> 39(12) 824–827. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6241720/&quot;>https://pubmed.ncbi.nlm.nih.gov/6241720</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AA05;
